Amgen reported Q1 2026 results on April 30 ↗ alongside an obesity pipeline update that confirmed the company's MariTide ↗ program is broadening across three fronts. MARITIME-1, the ongoing Phase 3 study of MariTide in adults with obesity or overweight, continues to enroll. MARITIME-2 EXTENSION, a study designed to evaluate how well MariTide maintains weight loss after the active reduction phase, has launched. Three Phase 3 studies in adults with type 2 diabetes are slated to start in 2026. A Phase 2b liver-fat-reduction study and a Phase 1 of the follow-on candidate AMG 513 round out the bench.
The architecture. MariTide is a peptide-antibody conjugate that activates the GLP-1 receptor and antagonizes the GIP receptor, with monthly or less-frequent dosing. The conjugate format is the differentiator. The peptide moiety provides the receptor-engagement specificity. The antibody half extends half-life dramatically, taking the dosing schedule from once-weekly (the standard for current GLP-1 drugs) to once-monthly or longer. For patients who tolerate GLP-1 mechanism but find the weekly injection schedule onerous, the value proposition is straightforward.
The mechanism is also unusual on the GIP side. Tirzepatide ↗ and the rest of the leading dual agonists are GLP-1 plus GIP agonists; both arms activate their respective receptors. MariTide is GLP-1 agonist plus GIP antagonist. The hypothesis behind the antagonist arm is that GIP receptor blockade may produce additional weight-loss-promoting effects through complementary metabolic pathways, while the agonism debate has been dominated by Lilly's success with tirzepatide. Phase 2 data on MariTide were mixed enough that the program's continued advance required a defensible commercial story; the maintenance-extension launch and three new T2D Phase 3 studies show the company is committed to the thesis through 2026 and beyond.
Where this fits in the field. The current commercial obesity-peptide market is structurally bipolar between Lilly (Mounjaro ↗, Zepbound ↗, Foundayo, with retatrutide ↗ arriving in 2027) and Novo Nordisk (semaglutide ↗ injectable, oral Ozempic ↗ Pill, CagriSema in pivotal). Amgen is the third meaningful entrant, with a different molecular design (peptide-antibody conjugate), a different dosing schedule (monthly or longer), and a different receptor configuration (GLP-1 agonist plus GIP antagonist rather than dual agonist). Even if MariTide does not match Mounjaro on raw weight loss, the dosing schedule alone could carve a meaningful patient population that prefers fewer injections per year and is willing to trade some efficacy for convenience.
The maintenance angle. The MARITIME-2 EXTENSION study is the part of the announcement that has medium-term competitive significance. Weight regain after stopping GLP-1 therapy is a documented phenomenon: patients who discontinue typically regain a meaningful fraction of lost weight within a year. A drug specifically positioned for the maintenance phase, with a less burdensome dosing schedule, addresses an unmet need that the current Mounjaro-Zepbound-Wegovy ↗ approach has not solved. Whether MariTide can demonstrate maintenance-phase efficacy that justifies a separate label or positioning is the open question MARITIME-2 will answer.
The diabetes expansion. Three Phase 3 T2D studies starting in 2026 reflects Amgen's view that MariTide can compete in the larger diabetes market beyond obesity. The competitive bar is high: Mounjaro generated $8.66 billion in Q1 2026 alone, and Novo's semaglutide franchise is in the same range. To carve share, MariTide will need to demonstrate either superior glycemic control, better tolerability, or the dosing-schedule advantage at sufficient magnitude to drive prescriber preference. The 2026 study starts mean readouts will land in 2027-2028.
The platform read. The peptide-antibody-conjugate architecture MariTide rides on is one of the underexplored design spaces for metabolic-disease drugs. Most current peptide-conjugate work in clinical practice is in oncology (Lutathera, Pluvicto, the established ADCs). MariTide is the leading metabolic-disease example, and the GLP-1R ↗ and GIPR ↗ target pages on peptidemodel will need explicit conjugate-architecture annotations as more programs of this class advance toward clinic.
What 2026 reveals. MARITIME-1 topline, expected within the next twelve to eighteen months, will determine whether the GLP-1-agonist plus GIP-antagonist mechanism delivers obesity outcomes competitive with the dual-agonist standard. MARITIME-2 will determine whether monthly-or-less-frequent dosing supports long-term weight maintenance. The 2026 T2D study starts will determine, eventually, whether Amgen has a credible diabetes franchise to add to the obesity bet.